10-Q: SS Innovations International Reports Increased Revenue but Faces Restatement and Internal Control Issues in Q3 2024

SS Innovations International reported a significant increase in revenue for the third quarter of 2024, but also disclosed the need to restate prior financial statements and identified material weaknesses in internal controls.

Summary

• SS Innovations International, Inc. (SSII) has released its quarterly report for the period ending September 30, 2024, showing a substantial increase in revenue compared to the same period last year.
• The company's revenue reached $15,025,717 for the nine months ended September 30, 2024, compared to $4,866,287 for the same period in 2023.
• However, the report also reveals that the company's previously issued financial statements for 2022 and 2023, as well as interim statements for certain quarters, need to be restated due to accounting errors.
• SSII has identified material weaknesses in its internal controls, including a failure to properly apply U.S. GAAP, a lack of written documentation for internal control policies, and insufficient segregation of duties within accounting functions.
• The company incurred a net loss of $11,699,076 for the nine months ended September 30, 2024, compared to a net loss of $4,060,806 for the same period in 2023, primarily due to increased stock compensation expenses.
• SSII sold 25 surgical robotic systems during the nine months ended September 30, 2024, and installed one system on a revenue share basis.
• As of September 30, 2024, the company has sold a total of 40 systems and installed 5 systems on a pay-per-use or revenue share basis.
• The company has raised $4.95 million through convertible promissory notes and $2.5 million through non-convertible promissory notes to fund its operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is strong revenue growth and product development, the need for a financial restatement and the identification of material weaknesses in internal controls are significant concerns. The increased net loss and reliance on debt financing also contribute to a negative sentiment.

Positives

• The company experienced a substantial increase in revenue, indicating strong sales growth.
• The company has successfully expanded its installed base of surgical robotic systems.
• The launch of the SSi Mantra 3 demonstrates ongoing product development and innovation.
• The company has secured additional funding through promissory notes to support its operations.

Negatives

• The company's financial statements for 2022 and 2023, as well as interim statements for certain quarters, need to be restated.
• Material weaknesses in internal controls have been identified, raising concerns about the reliability of financial reporting.
• The company's net loss has significantly increased, primarily due to higher stock compensation expenses.
• The company has a history of losses and an accumulated deficit of $41,901,082 as of September 30, 2024.

Risks

• The need to restate prior financial statements could negatively impact investor confidence.
• Material weaknesses in internal controls could lead to further accounting errors and potential regulatory issues.
• The company's reliance on debt and equity raised in private offerings and shareholder loans may not be sustainable in the long term.
• The company's ability to secure additional funding is not guaranteed, which could hinder expansion plans.
• Ongoing litigation in the Bahamas regarding a subsidiary could result in financial losses and legal costs.
• The company's expansion plans could be curtailed if adequate financing is not obtained.

Future Outlook

The company anticipates regulatory approvals in the United States and the EU in the latter part of 2025. The company expects to require substantial funds for expansion of its manufacturing capacity, conducting global clinical trials, expanding its senior level manpower, leasing additional space, augmenting working capital and establishing regional marketing offices.

Management Comments

• The company is constantly working on making its surgical robotics technology more user-friendly, easy to operate and cost effective so as to make its benefits reach larger communities across the globe.
• The company is relentlessly pursuing its vision of increasing the penetration of robotics surgeries in regions and countries which were hitherto completely forgotten.

Industry Context

The company is aiming to democratize access to advanced surgical robotics technologies at relatively affordable costs, addressing the limited access to such systems in developing countries. The company's focus on cost-effectiveness and user-friendliness aligns with the broader industry trend of making advanced medical technologies more accessible globally.

Comparison to Industry Standards

• While the company's revenue growth is impressive, the need for a financial restatement and the identification of material weaknesses in internal controls are significant concerns that are not typical for established medical device companies.
• Companies like Intuitive Surgical and Stryker, which are leaders in the surgical robotics market, have robust internal controls and a history of reliable financial reporting.
• SSII's focus on affordability and accessibility is a differentiator, but it needs to address its internal control issues to compete effectively with established players.
• The company's sales of 40 systems and 5 installations on a pay-per-use basis is a relatively small number compared to the global leaders in the surgical robotics market.

Legal Proceedings

• An ex-shareholder of Otto Pvt Ltd. commenced litigation in the Bahamas, seeking legal confirmation that it holds 9,000 shares in Otto.
• Dr. Srivastava has filed an action in the Bahamas to confirm the cancellation of the shares and reconfirm their ownership.

Related Party Transactions

• The company raised $2.45 million through a private offering of 7% One-Year Convertible Promissory Notes from two affiliates, including Sushruta Pvt Ltd.
• The company borrowed $2.0 million from Sushruta to meet working capital needs.
• The company borrowed an additional $500,000 from Sushruta.
• There was US $1,160,649 in amounts due from related parties as of September 30, 2024.

Stakeholder Impact

• Shareholders may be concerned about the need to restate prior financial statements and the identified material weaknesses in internal controls.
• Employees may be affected by the company's efforts to remediate internal control issues.
• Customers may be impacted by any potential delays or disruptions caused by the company's financial and operational challenges.
• Creditors may be concerned about the company's increased net loss and reliance on debt financing.

Next Steps

• The company will amend this report as soon as practicable after the audit and required review are completed.
• The company will implement a new ERP system to integrate all business functions within the accounting and financial department.
• The company will continue to address and remediate the material weaknesses in internal controls.
• The company will continue to make efforts to raise long term funds by way of equity or loans.

Key Dates

Keywords

surgical robotics, financial restatement, internal controls, revenue growth, promissory notes, stock compensation, net loss, SSI Mantra, medical devices, healthcare technology